Join
Live feed
·
PRReleasevia Quantisnow
Biomea Fusion Inc. logo

Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

ByQuantisnow·Wall Street's wire, on your screen.
BMEA· Biomea Fusion Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BMEA (Biomea Fusion Inc.) and more on Quantisnow.